These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Treatment of hemangioma in oral and maxillofacial region with intralesional injection of pingyangmycin].
    Author: Liu XJ, Qing ZP, Li KL.
    Journal: Shanghai Kou Qiang Yi Xue; 2001 Dec; 10(4):295-8. PubMed ID: 14993954.
    Abstract:
    OBJECTIVE: To investigate the indication and long term treatment results of intralesional injection of Pingyangmycin for hemangiomas in oral and maxillofacial regions. METHODS: Between June 1986 and June 2000, 1040 patients with maxillofacial hemangiomas were treated by intralesional injection of Pingyangmycin PYM . There were 312 males and 712 females. The types of hemangiomas included capillary 436, cavernous 238, mixed 260, arterial venous malformation 8 and port wine stain 9 . The injection was performed in stages and multi sites, repeated after 14 to 21 days for 2 to 3 times as one course. RESULTS: All the patients were followed up for 1 to 14 years. The cure rates of capillary, mixed and cavernous hemangioma were 96.40%, 92.20% and 67.20%, respectively. No effect was found for arterial venous malformations. The best dose effect was attained in 1mg/cm(2). The best concentration of Pingyangmycin was 1mg/ml for capillary hemangioma and the concentration may be higher for cavernous hemangiomas. Fever occurred in 6.54% of the cases. Serious complications associated with Pingyangmycin injection, such as pulmonary fibrosis were not found. CONCLUSION: Intralesional injection of Pingyangmycin can be used as the therapy of choice for capillary, mixed and cavernous hemangiomas in oral and maxillofacial region. The advantages included a high cure rate, safety, short course, manipulation with ease and fewer side effects.
    [Abstract] [Full Text] [Related] [New Search]